Browsing the "CASMI Views" Category

How much do we value our good health?

reformatted-slider-graphic-101 1

Last week saw coverage by the media of NICE recommendation of two new drugs to treat breast cancer – palbociclib and ribociclib. These are a new class of small molecule drugs, which inhibit DNA synthesis and hence inhibit tumour growth. Both are tablets, and are indicated for use in previously [...]

November 27, 2017 Maeve Waite CASMI Views 0

What else did the Cancer Drugs Fund do for us? Real-world data?

reformatted-slider-graphic-101 1

The Cancer Drugs Fund (CDF) in England – in its original incarnation between October 2010 and April 2016 – was a ring-fenced fund to provide access to cancer drugs not routinely funded by the NHS. Following reform during 2016, the CDF now offers a managed access option for cancer drugs [...]

September 4, 2017 Maeve Waite CASMI Views 0

Convergent evolution: cancer drug access in England and Scotland

reformatted-slider-graphic-101 1

The National Institute for Health and Care Excellence (NICE) in England, and the Scottish Medicines Consortium (SMC) in Scotland, face the same challenge of making drug funding recommendations that are fair to all users of the NHS and acceptable to society. Health technology appraisal is a devolved responsibility, so it [...]

August 21, 2017 Maeve Waite CASMI Views 0

NHS England and NICE changes to evaluation of drugs for rare conditions

reformatted-slider-graphic-101 1

In March this year, NICE’s board agreed a proposal to introduce Quality-Adjusted Life Years (QALYs) as the measure of value for Highly Specialised Technologies (HST – products to treat very rare conditions), with a limit of £100 000 per QALY, below which the treatment would automatically be funded.  In response [...]

June 20, 2017 Maeve Waite CASMI Views 0

Contrasting fortunes of immunotherapy drugs in first-line treatment of lung cancer

policy and impact_slider

The pharmaceutical press were quick to express their disappointment earlier this year at a draft decision by NICE, not to fund pembrolizumab (Keytruda: MSD) for first-line treatment of metastatic non-small cell lung cancer. The Appraisal committee concluded there was such uncertainty in the evidence base that it was impossible to [...]

May 22, 2017 Maeve Waite CASMI Views 0

What did the Cancer Drugs Fund do for us?


Many of us woke last Friday morning to news coverage of the Cancer Drugs Fund, with reporting describing the Fund as “a waste of money” based on a paper published in Annals of Oncology by Aggarwal et al. The paper lays out a series of evaluations of the drugs provided [...]

May 9, 2017 Maeve Waite CASMI Views 0

Funding of ultra-orphan drugs in Scotland and England

slider CASMI_graphic_10

Two years on from reforms to the Scottish Medicines Consortium’s processes for evaluation drugs for end-of-life and rare conditions implemented in 2014, Dr Brian Montgomery was asked by the Scottish Government to review their impact on access. The result was a wide-ranging report covering multiple aspects of drug access, with [...]

February 13, 2017 Maeve Waite CASMI Views 0

Cancer drug access and devolution: the case of nivolumab, December 2016

reformatted slider graphic 10

Cancer drug access has been in the headlines again this week, following publication of articles by journalist A A Gill, in which he commented on (un)availability of the drug nivolumab for lung cancer on the NHS in England. In particular, his writing drew attention to the fact that the drug [...]

February 8, 2017 Maeve Waite CASMI Views 0

Emerging Challenges in Research Ethics


CASMI Fellow, Jonathan Montgomery, had an opportunity to share his thoughts on emerging challenges in research ethics with members of the Ministry of Defence Research Ethics Committee in January. He identified a series of trends that placed the traditional paradigm under pressure. The closer integration of researchers and participants whereby [...]

February 1, 2017 Maeve Waite CASMI Views 0

CASMI Academic Agenda: A focus on ‘pull’ factors


CASMI’s mission is to help make the medical innovation process more efficient and sustainable, recognising that there is much unmet clinical need to address and the development and adoption of new drug solutions are slow and costly. Since inception we have seen the medical innovation process as a circular one [...]

December 20, 2016 Maeve Waite CASMI Views 0